Washington University School of Medicine

Digital Commons@Becker
Open Access Publications
2006

PLCγ2
PLC 2 regulates osteoclastogenesis via its interaction with ITAM
proteins and GAB2
Dailing Mao
Washington University School of Medicine in St. Louis

Holly Epple
Washington University School of Medicine in St. Louis

Brian Uthgenannt
Washington University School of Medicine in St. Louis

Deborah V. Novack
Washington University School of Medicine in St. Louis

Roberta Faccio
Washington University School of Medicine in St. Louis

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Recommended Citation
Mao, Dailing; Epple, Holly; Uthgenannt, Brian; Novack, Deborah V.; and Faccio, Roberta, ,"PLCγ2 regulates
osteoclastogenesis via its interaction with ITAM proteins and GAB2." The Journal of Clinical Investigation.
116,11. 2869-2879. (2006).
https://digitalcommons.wustl.edu/open_access_pubs/1551

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been
accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker.
For more information, please contact vanam@wustl.edu.

Downloaded on August 5, 2013. The Journal of Clinical Investigation. More information at www.jci.org/articles/view/28775

Research article

PLCγ2 regulates osteoclastogenesis via its
interaction with ITAM proteins and GAB2
Dailing Mao,1 Holly Epple,2 Brian Uthgenannt,1 Deborah V. Novack,3 and Roberta Faccio1
1Department

of Orthopaedic Surgery and Cell Biology, 2Department of Medicine and Cell Biology, and 3Department of Medicine,
Division of Bone and Mineral Diseases, Washington University School of Medicine, St. Louis, Missouri, USA.

Excessive bone loss in arthritic diseases is mostly due to abnormal activation of the immune system leading to
stimulation of osteoclasts. While phospholipase Cγ (PLCγ) isoforms are known modulators of T and B lymphocyte–mediated immune responses, we found that blockade of PLCγ enzymatic activity also blocks early osteoclast
development and function. Importantly, targeted deletion of Plcg2 in mice led to an osteopetrotic phenotype.
PLCγ2, independent of PLCγ1, was required for receptor activator of NF-κB ligand–induced (RANKL-induced)
osteoclastogenesis by differentially regulating nuclear factor of activated T cells c1 (NFATc1), activator protein–1 (AP1), and NF-κB. Specifically, we show that NFATc1 upregulation is dependent on RANKL-mediated
phosphorylation of PLCγ2 downstream of Dap12/Fc receptor γ (Dap12/FcRγ) receptors and is blocked by the
PLCγ inhibitor U73122. In contrast, activation of JNK and NF-κB was not affected by U73122 or Dap12/FcRγ
deletion. Interestingly, we found that in osteoclasts, PLCγ2 formed a complex with the regulatory adapter molecule GAB2, was required for GAB2 phosphorylation, and modulated GAB2 recruitment to RANK. Thus, PLCγ2
mediates RANKL-induced osteoclastogenesis and is a potential candidate for antiresorptive therapy.
Introduction
Bone erosion is a major hallmark of rheumatoid arthritis and is
solely executed by the bone-resorbing cells, the osteoclasts (OCs)
(1). These cells arise from macrophage precursors and differentiate
into the mature polykaryon after stimulation with receptor activator of NF-κB ligand (RANKL) and M-CSF (2). OCs are recruited
to sites of inflammation or differentiate at these sites owing to
elevated levels of local RANKL secreted by cells in the inflamed
tissue. Levels of TNF-α, IL-1, and M-CSF are also elevated during
inflammatory responses and they collaborate with RANKL to further increase the rate of OC formation and bone resorption (3–6).
Binding of RANKL to receptor activator of NF-κB (RANK) leads
to receptor trimerization, followed by the recruitment of TRAF6,
which acts as a key adapter to assemble signaling proteins that
direct OC-specific gene expression (2). Both NF-κB and activator protein–1 (AP1) are rapidly induced in response to RANKL,
following the activation of IκB kinase 1/2 (IKK1/2) and JNK,
respectively (2, 7–9). Interfering with IKK1/2 or JNK1 signaling
pathways blocks in vitro and in vivo osteoclastogenesis (10–12).
Targeted mutagenesis of the p50/p52 components of NF-κB (13,
14) as well as the c-Fos component of AP1 (15) results in osteopetrosis due to a block in osteoclastogenesis. Further, a recent
finding indicates that activation of JNK and NF-κB pathways
requires the phosphorylation and the recruitment of the Grb2binding adapter protein, GAB2, to RANK (16). Consistent with
these observations, GAB2–/– mice exhibit an osteopetrotic phenotype due to aberrant OC differentiation (16).
In addition to the known roles of AP1 and NF-κB pathways in
osteoclastogenesis, recent studies have highlighted the role of the
Nonstandard abbreviations used: AP1, activator protein–1; BMM, BM macrophage;
FcRγ, Fc receptor γ; IP3, inositol-1,4,5-triphosphate; ITAM, immune receptor tyrosine
activation motif; NFATc1, nuclear factor of activated T cells c1; OB, osteoblast; OC,
osteoclast; PLC, phospholipase C; RANK, receptor activator of NF-κB; RANKL, RANK
ligand; SFK, Src family kinase; TRAP, tartrate-resistant acid phosphatase.
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nuclear factor of activated T cells c1 (NFATc1), a calcineurin- and
calcium-regulated transcription factor, as a master transcription
factor in this process (17, 18). The importance of NFATc1 in OC
development has been buttressed by the fact that NFATc1–/– embryonic stem cells cannot differentiate into OCs. Furthermore, overexpression of the WT protein stimulates OC development from
embryonic stem cells in a RANKL-independent manner (18).
Interestingly, the ability of NFATc1 to mediate osteoclastogenesis
is strictly connected to the c-Jun pathway (19). Transgenic mice
expressing a dominant negative form of c-Jun have osteopetrosis due to defective osteoclastogenesis that cannot be rescued by
NFATc1 overexpression in OCs (19).
Immune receptor tyrosine activation motifs (ITAMs) are important signaling components for a number of receptors in the immune
system, and they have been recently identified as costimulatory
signals in RANKL-induced osteoclastogenesis (20). The 2 ITAMcontaining adapters, Dap12 and the γ chain of Fc receptor (FcRγ),
have a profound impact on OCs by modulating RANKL-mediated
calcium influx and NFATc1 expression. In humans, mutation in
the Dap12 gene is responsible for Nasu-Hakola disease, characterized by multiple bone cysts associated with a unique form of neurodegeneration (21). Deletion of Dap12 and FcRγ (Dap12–/–FcRγ–/–), in
mice, leads to severe osteopetrosis due to defective OC development
(20–22). In vitro triggering of either receptor by crosslinking with
an antibody accelerates RANKL-induced OC differentiation (23).
However, in the absence of RANKL, these receptor-mediated signals
alone are not sufficient to induce OC differentiation.
The phospholipase C (PLC) family regulates PKC activation,
intracellular calcium levels, and NFAT expression in hematopoietic systems in response to the stimulation of immune receptors
(24–27). PLC cleaves the membrane phospholipid phosphatidyl
inositol-4,5-biphosphate (PIP2) into the second messenger molecules inositol-1,4,5-triphosphate (IP3) and diacylglycerol (DAG).
IP3 directly increases intracellular calcium levels by inducing the
release of endoplasmic reticulum calcium stores, while DAG activates PKC at the plasma membrane.
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Figure 1
PLCγ inhibition blocks osteoclastogenesis and actin ring
formation. (A) WT OCs were generated with RANKL (100
ng/ml) and M-CSF (10 ng/ml) in the presence of the PLC
inhibitor U73122 (5 μM) for 4 days on plastic. In some wells,
the media with the inhibitor was replaced with fresh osteoclastogenic media, and cells were allowed to differentiate
for 4 more days (Withdrawal U73122). (B) WT OCs were
grown on dentin with or without U73122 for 10 days. Cells
were then removed and pits stained with hematoxylin red
(Magnification, ×200). CTR, control. (C) WT OCs were generated on dentin in the absence of the inhibitor, then treated
with vehicle or U73122 for 1 hour. Cells were fixed and actin
stained using FITC-phalloidin (Magnification, ×200).

The PLCγ family consists of 2 members, PLCγ1 and PLCγ2
(24–26). Both isoforms require phosphorylation on specific tyrosine residues for their catalytic activity. In addition, they contain
2 SH2 and 1 SH3 domains through which they can interact with
other signaling proteins, suggesting adapter function. PLCγ1 is
widely distributed, while PLCγ2 is primarily limited to cells of
hematopoietic lineage (24). Mice deficient in PLCγ1 develop normally to embryonic day 8.5 but die soon after due to undefined
defects in growth and development (28). The disruption of PLCγ2
in mice does not result in embryonic lethality, but animals show
internal bleeding, decreased B cell number and function, defective
platelet aggregation to collagen, and a block in Fc receptor–mediated responses in mast cells and NK cells (29–31).
Although NF-κB, AP1, and NFATc1 are all critical for RANKLinduced osteoclastogenesis (9, 18, 32), due to their ubiquitous
expression, selective therapies targeting these signaling pathways
in OCs are not yet in clinical use. In this study, we show that targeted deletion of Plcg2 in mice results in an in vivo osteopetrotic
phenotype, independent of PLCγ1. In vitro, Plcg2-null cells fail to
form multinucleated OCs and exhibit decreased RANKL-mediated
NFATc1 expression; impaired JNK, c-Jun, and IκBα phosphorylation; and thus defective AP1 and NF-κB activation. Our data reveal
a role for PLCγ2 in bone homeostasis apart from its contribution
to B cell development. The combined effect of PLCγ2 on lymphocyte and OC differentiation could represent a novel target for the
treatment of inflammatory osteolytic diseases.
Results
Inhibition of PLCγ enzymatic activity blocks OC differentiation and disrupts actin ring formation. PLCγ isoforms are known activators of
the NFAT family of transcription factors in lymphoid cells, downstream of immune receptor signaling via ITAMs (33). Since NFAT
and ITAMs are both critical regulators of OC differentiation and
cells lacking the ITAM-containing adapters Dap12/FcRγ display
severe osteopetrosis (20), we asked whether PLCγ family members
were also required for efficient OC differentiation and function.
We therefore tested the capacity of the PLCγ inhibitor U73122 to
2870
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block OC formation and bone resorption. Addition of U73122 to
the culture media blocked OC development, as demonstrated by
the absence of tartrate-resistant acid phosphatase–positive (TRAPpositive) cells, compared with the numerous multinucleated OCs
obtained in wells cultured only with RANKL and M-CSF (Figure
1A). Replacing the media with fresh osteoclastogenic media lacking the inhibitor restored the ability of the cells to differentiate,
indicating that the compound was not toxic to the cells (Figure 1A).
Culture of OCs on dentin in the presence of U73122 blocked bone
resorption (Figure 1B). Furthermore, addition of U73122 to mature
resorbing cells rapidly disrupted the organization of the actin rings,
indicating that this compound can block bone resorption independent of its capacity to affect differentiation (Figure 1C).
PLCγ2 regulates bone mass in vivo. To determine whether PLCγ1,
PLCγ2, or both are required for OC formation, we turned to the
analysis of mice lacking these proteins. Plcg1–/– mice die in utero
by day 9, rendering the analysis of their bone phenotype difficult.
Plcg2–/– mice, however, are viable. Thus, femurs from 4-month-old
sex-matched WT and Plcg2–/– mice were subjected to histological examination (Figure 2, A–E) and μCT analysis (Figure 2, F–I).
Plcg2–/– mice had a more than 3-fold increase in the percentage of
trabecular bone volume versus total bone volume compared with
their WT counterparts, as determined by histological examination (Figure 2B) and as shown in μCT reconstructed 3D images
(Figure 2F). Histomorphometric analysis also indicated that the
number of osteoblasts (OBs) per bone perimeter was similar in
WT and Plcg2–/– mice (Figure 2C), while the number of OCs per
bone perimeter and the OC surface were significantly decreased
in the null animals (Figure 2, D and E). The number of the trabeculae (Figure 2G) and their thickness (Figure 2H) were significantly higher in the Plcg2–/– compared with WT mice, while the
space between the trabeculae was smaller (Figure 2I). Thus, PLCγ2
regulates bone mass in vivo.
PLCγ2 is required for OC differentiation. To determine whether PLCγ2
modulates the capacity of OBs to form bone or to promote OC differentiation, primary OBs were isolated from newborn mice, and
their capacity to mineralize extracellular matrix or induce osteo-
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Figure 2
Osteopetrosis in mice lacking PLCγ2. (A)
TRAP staining of decalcified histological sections of WT and Plcg2–/– proximal femurs.
Magnification, ×40. (B–E) Quantitative analysis of bone parameters from histological sections of WT and Plcg2–/– bone femurs (n = 8)
showing: percentage of bone volume versus
total bone volume (BV/TV) (B); number of
OBs (nOB) per bone perimeter (C); number
of OCs (nOC) per bone perimeter (D); fraction of trabecular surface covered by OCs (E).
(F) 3D reconstitution of μCT scans of WT and
Plcg2–/– femurs. (G–I) 3D trabecular quantitative parameters of bone structure (n = 6).
Graphs show mean ± SEM, with significant
differences compared with WT indicated.

clastogenesis in a coculture system was examined. Plcg2–/– OBs
were indistinguishable from their WT counterparts in their ability to form bone nodules in response to β-glycerolphosphate (WT,
14 ± 2.08 nodules/well versus Plcg2–/–, 14.6 ± 1.65 nodules/well)
(Figure 3A). This finding was also supported by the in vivo analysis
of bone mineral apposition determined by calcein double-labeling
(Figure 3B), which revealed no significant difference in bone formation rates (BFRs) and mineral apposition rates (MARs) between WT
(BFR, 0.8938 ± 0.1042 μm3/μm2/d; MAR, 0.5927 ± 0.0219 μm/d)
and Plcg2–/– animals (BFR, 0.8450 ± 0.1629 μm3/μm2/d; MAR,
0.4015 ± 0.0876 μm/d). To determine whether Plcg2–/– OBs are capable of supporting OC differentiation, BM macrophages (BMMs)
from WT mice were cocultured with either WT or Plcg2–/– OBs in
the presence of 1,25 vitamin D3 (1,25 Vit D3). Cultures were stained
for TRAP to identify OCs. WT BMMs became TRAP-positive, multinucleated cells when cultured with WT OBs (OCs, 9 ± 1.07/well)
or null OBs (OCs, 7 ± 0.44/well), indicating that the expression of
PLCγ2 in OBs is not required to support osteoclastogenesis. However, in a parallel experiment, BMMs from Plcg2–/– mice failed to form
mature OCs in the coculture system, independent of the source of
the OBs (Figure 3C). These results suggest that the increased in vivo
bone mass observed in Plcg2–/– mice was not due to aberrant OB
activity but was dependent on an intrinsic defect in the OC lineage.
We therefore cultured primary BMMs with M-CSF and RANKL for
5 days, in the absence of OBs or stromal cells. The osteoclastogenic
response of Plcg2–/– BMMs to RANKL and their capacity to resorb
bone were arrested (Figure 3D; WT OCs, 33.2 ± 1.74/well versus
Plcg2–/– OCs, not detected). Increasing the concentration of M-CSF
from 10 to 100 ng/ml, a condition that partially rescued the osteoclastogenesis in cells lacking the ITAM-bearing adapter Dap12 (34),
did not enhance Plcg2–/– OC differentiation (data not shown).
To determine which stage of OC differentiation is PLCγ2 dependent, the levels of early osteoclastogenic markers TRAP, cathepsin K,
NFATc1, and calcitonin receptor, a late OC marker, were determined by real-time PCR analysis in BMMs cultured with RANKL
The Journal of Clinical Investigation

(100 ng/ml) and M-CSF (10 ng/ml) up to 4 days. The expression
of TRAP, cathepsin K, and NFATc1 increased within 24–48 hours
after RANKL stimulation in WT but not in Plcg2–/– cells (not
shown). On day 4, the levels of these genes were maximal in WT
cells but dramatically lower in the null cells (Figure 4, A–D). Similarly, calcitonin receptor was detected after 4 days of treatment
with RANKL only in WT OCs, suggesting that Plcg2–/– cells have
an early block of OC development. Confirming mRNA expression, protein levels of NFATc1 were significantly higher in total
cell lysates of day 4 WT OCs than in null cells, both under basal
conditions and following 60 minutes of RANKL stimulation (Figure 4E). Together, these data indicate that PLCγ2 is required at
early stages of OC development.
PLCγ2 is required for efficient RANKL-induced activation of AP1 and
NF-κB in developing OCs. To further understand whether PLCγ2 is
a downstream mediator of RANKL, M-CSF, or both during OC
differentiation, we analyzed MAPK activation by BMMs in culture
with M-CSF for 3 days. Activation of ERK and JNK in response to
M-CSF occurred normally in BMMs lacking PLCy2 (Figure 5A).
Similarly, ERK was normally phosphorylated in the null cells in
response to RANKL (Figure 5B). In contrast, RANKL-mediated
JNK phosphorylation was retarded and reduced in the absence
of PLCγ2 (Figure 5B), and activation of c-Jun (by phosphorylation) was also decreased in both the cytoplasm and the nucleus
(Figure 5, B and C). This result is particularly compelling, since
JNK/c-Jun activates the AP1 complex, and inhibition of JNK activity blocks RANKL-induced OC development (19). Thus, to determine whether the decreased phosphorylation of JNK observed in
Plcg2–/– BMMs stimulated with RANKL could result in deficient
AP1 activation, nuclear extracts from WT and Plcg2–/– cells were
subjected to EMSA analysis following RANKL stimulation. The
activation of AP1 was abolished in RANKL-stimulated Plcg2–/–
BMMs (Figure 5D, top panel).
Since NF-κB is the other major signaling pathway required for
efficient osteoclastogenesis, and PLCγ isoforms have been shown
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To determine whether lack of
PLCγ2 was abrogating the activation
of PLCγ1 in response to RANKL and
M-CSF, WT and Plcg2–/– OC precursors
(BMMs grown in RANKL-containing media for 2 days) were stimulated
with RANKL or M-CSF. Interestingly,
RANKL-mediated PLCγ1 phosphorylation was barely measurable in both WT
cells and cells lacking PLCγ2 (Figure
6B) despite detectable levels of PLCγ1
protein in both cell types. In contrast, a
strong PLCγ1 phosphorylation signal
was observed after M-CSF stimulation
in WT and Plcg2–/– cells (Figure 6C).
Since costimulatory signals are
required for RANKL-mediated calcium oscillation and NFATc1 expression, we determined whether PLCγ2
phosphorylation was dependent on
the RANKL costimulatory receptors
Dap12 and FcRγ. We found that PLCγ2
phosphorylation and NFATc1 nuclear
localization were decreased in Dap12–/–
FcRγ–/– cells treated with RANKL (Figure 6, E and F). Reexpression of Dap12,
Figure 3
PLCγ2 is required for osteoclastogenesis. (A) Bone nodule formation in WT and Plcg2–/– OBs cul- but not empty vector, in the double
tured with ascorbic acid and β-glycerolphosphate. (B) Double labeling of calvarial bones showing the null OCs (Figure 6D) completely
degree of bone formation (BFR) of WT and Plcg2–/– mice injected on day 0 and day 7 with calcein restored PLCγ2 phosphorylation (Fig(WT BFR, 0.8938 ± 0.1042 μm3/μm2/d; WT mineral apposition rate [MAR], 0.5927 ± 0.0219 μm/d; ure 6E) and expression of NFATc1 in
Plcg2–/– BFR, 0.8450 ± 0.1629 μm3/μm2/d; Plcg2–/– MAR, 0.4015 ± 0.0876 μm/d). (C) WT and Plcg2–/– the nucleus (Figure 6F). Thus, PLCγ2 is
BMMs cultured with WT and Plcg2–/– OBs in the presence of 10–8 M 1,25 Vit D3. After 14 days, cells
phosphorylated downstream of Dap12
were fixed and TRAP stained to detect the presence of multinucleated OCs. (D) TRAP-stained OCs
generated with RANKL (100 ng/ml) and M-CSF (10 ng/ml) for 5 days (top panel) and bone resorptive in an SFK-dependent manner, followpits generated from OCs plated on dentin for 7 days. Pits were stained with hematoxylin red. (E) WT ing RANKL stimulation.
PLCγ2 catalytic activity is required for
and Plcg2–/– BMMs retrovirally transduced with vector alone (pMX) or with Flag-tagged PLCγ2 were
allowed to differentiate in osteoclastogenic media for 5 days, then stained for TRAP. Magnification, NFATc1 upregulation but not for JNK and
×200 (A, C–E); ×100 (B).
IκBα phosphorylation. Our data indicate
that PLCγ2 regulates NFATc1 and
activates JNK and IκBα. In contrast,
to modulate T cell and B cell receptor–mediated NF-κB activa- Dap12/FcRγ modulates NFATc1 (Figure 6F) but not JNK (Figure
tion, we hypothesized that this pathway could also be regulated 6E) or IκBα (20). Thus, we hypothesized that PLCγ2 regulates JNK
by PLCγ2 in OCs. Nuclear extracts from WT and Plcg2–/– BMMs and IκBα independent of Dap12/FcRγ. To determine whether
stimulated with RANKL were subjected to EMSA analysis, and PLCγ2 catalytic activity is required for JNK and IκBα phosphordata show that in the null cells, activation of NF-κB was virtually ylation, WT OC precursors, cultured in the presence of the PLC
absent (Figure 5D, bottom panel). In agreement with this result, inhibitor U73122 (5 μM), were stimulated with RANKL for 0 to
IκBα phosphorylation and nuclear translocation of p65 were also 60 minutes (Figure 7A). While dampening NFATc1 upregulation,
decreased in Plcg2–/– BMMs (Figure 5, B and C). Collectively, these the inhibitor had no effect on p-JNK and p-IκBα, suggesting that
data suggest that PLCγ2 plays a central role in RANKL-mediated the catalytic activity of PLCγ2 is not required for phosphorylation
osteoclastogenesis by controlling activation of AP1 and NF-κB of JNK and IκBα.
and upregulation of NFATc1.
Mutations of 2 histidine residues, conserved among all PLC famPLCγ2 is phosphorylated by RANKL via Dap12-mediated costimulatory sig- ily members, have been shown to inhibit the enzymatic activity
nals in a Src family kinase–dependent manner. Having shown that PLCγ2 of PLCγ1 by 90%–95% in vitro (35). Thus, we generated a PLCγ2
is required for the activation of osteoclastogenic signaling pathways catalytic inactive construct carrying the double histidine 327/372
downstream of RANKL, we turned to the mechanism by which PLCγ2 to phenylalanine mutation (PLCγ2 H/F). This mutant was provitself is activated in OCs. In immune cells, PLCγ isoforms are tyrosine en to be lipase inactive compared with WT full-length PLCγ2 in
phosphorylated in a Src family kinase–dependent (SFK-dependent) 293 cells (data not shown). Plcg2–/– cells transduced with PLCγ2
manner (24). Incubation of WT cells with the SFK inhibitor PP2 H/F were incapable of generating mature, TRAP-positive OCs
(5 μM) completely blocked RANKL-mediated PLCγ2 phosphoryla- compared with cells expressing WT PLCγ2 (Figure 7B) or of protion and NFATc1 upregulation (Figure 6A), demonstrating a concor- moting NFATc1 upregulation (Figure 7C). In contrast, the abildant dependence on SFK in OC lineage cells.
ity of PLCγ2 H/F to mediate JNK and IκBα phosphorylation was
2872
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Figure 4
PLCγ2 regulates NFATc1 levels and the expression of early
osteoclastogenic genes. (A–D) Real-time PCR analysis of
osteoclastogenic markers in WT and Plcg2–/– cells in culture with M-CSF alone (d0) or with RANKL (100 ng/ml) plus
M-CSF (10 ng/ml) for 4 days (d4). Data are normalized relative to β-actin. ND, not detected. Significant differences compared with WT are shown. (E) Expression levels of NFATc1
protein in total cell lysates from day 4 WT and Plcg2–/– OCs,
starved for 6 hours and stimulated with RANKL for 0, 5, 20,
and 60 minutes. PLCγ1 and PLCγ2 levels are shown. β-Actin
served as loading control.

indistinguishable from that of WT PLCγ2 (Figure 7D). These data
indicate that PLCγ2 can modulate RANK-mediated signaling independent of its catalytic activity by acting as an adapter molecule.
One potential interacting protein is GAB2, which associates with
RANK and mediates RANK-induced activation of NF-κB and

JNK but not NFATc1 (16). Furthermore, GAB2 has been
shown to bind PLCγ2 in mast cells (36). To determine
whether PLCγ2 binds to GAB2 in OCs, we reciprocally
immunoprecipitated GAB2 and PLCγ2 and found that the
2 molecules associated (Figure 7E). Immunoprecipitation
with IgG control antibodies revealed the absence of nonspecific bands (data not shown). To further determine
whether PLCγ2 modulates GAB2 activation or its recruitment to RANK, WT and Plcg2–/– BMMs, treated with
RANKL, were immunoprecipitated with an anti-GAB2
Ab (Figure 7F) or with rabbit IgG control Ab (data not
shown), followed by immunoblotting with phosphotyrosine (4G10) and RANK. Results showed that PLCγ2
modulates GAB2 phosphorylation and its association
with RANK, suggesting that this may be the mechanism
by which PLCγ2 controls AP1 and NF-κB activation.
TNF-α cannot reverse the arrested capacity of PLCγ2-null cells to
became OCs. The data presented above show that PLCγ2 is central
in RANKL signaling. In OCs, TNF-α appears to be the dominant
cytokine mediating inflammatory osteolysis and augments the

Figure 5
PLCγ2 modulates RANKL-mediated signaling. (A) Activation of ERK and JNK in
WT and Plcg2–/– BMMs in response to
M-CSF (100 ng/ml). PLCγ1 and PLCγ2
levels are shown. (B) Western blot analysis of phospho-ERK, phospho-JNK,
phospho–c-Jun, and phospho-IκBα in
total cell lysates from WT and Plcg2–/–
BMMs stimulated with RANKL (100 ng/
ml) for the indicated times. β-Actin blots
served as loading control for A and B.
(C) Nuclear levels of phospho–c-Jun
and p65 in nuclear extracts from WT and
Plcg2–/– BMMs stimulated with RANKL.
(D) The same samples used in C were
subjected to AP1 and NF-κB nonradioactive EMSA analysis. To control for
binding specificity, a concentration of
unlabeled oligonucleotides (U.O.) 200fold greater than that recommended by
the manufacturer was added to nuclear
extracts from WT cells stimulated with
RANKL for 60 minutes. SP1 served as
loading control for C and D.
The Journal of Clinical Investigation
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Figure 6
PLCγ2 is activated by RANKL via Dap12/FcRγ in an SFK-dependent manner. (A) WT OC precursors (preOCs; BMMs grown in RANKL-containing media for 2 days) cultured with the SFK inhibitor PP2 (5 μM) or vehicle (DMSO) were stimulated with RANKL and subjected to Western blot
analysis to detect phosphorylated levels of PLCγ2, Src, and NFATc1. β-Actin served as control. (B) PLCγ1 and PLCγ2 phosphorylation in response
to RANKL were measured by Western blot analysis in WT and Plcg2–/– preOCs. PLCγ1 and PLCγ2 levels are shown. (C) PLCγ1 and PLCγ2 phosphorylation in response to 5 minutes of treatment with either M-CSF or RANKL in WT and Plcg2–/– preOCs. β-Actin served as control. (D) Expression levels of endogenous Dap12 and Flag-tagged Dap12 retrovirally transduced in Dap12–/–FcRγ–/– BMMs are shown. ΔKO, Dap12–/–FcRγ–/–. (E)
PLCγ2 phosphorylation was measured by Western blot analysis in WT, Dap12–/–FcRγ–/–, or Dap12–/–FcRγ–/– preOCs reconstituted with WT Dap12
stimulated with RANKL for the indicated times. Phospho-JNK is also shown. β-Actin served as loading control. (F) Nuclear localization of NFATc1
in WT and Dap12–/–FcRγ–/– OCs retrovirally transduced with pMX or Flag-tagged Dap12 is shown in red (left panels). Actin staining is shown in
green, and nuclei, stained with DAPI, are shown in blue (right panels) (objective, ×20). Enlarged images (2.5-fold) show nuclear localization of
NFATc1 (red) and nuclei stained with DAPI (blue) of representative cells located in the center of the photographed field.

osteoclastogenic potential of RANKL-exposed OC precursors
(3). Due to the capacity of TNF-α to phosphorylate JNK and
IκBα in BMMs and OCs (37), we tested its effect in modulating
the above-mentioned signaling pathways in cells lacking PLCγ2.
TNF-α–mediated phosphorylation of JNK and IκBα occurred
similarly in WT and null cells (Figure 8A). Furthermore, TNF-α
was not capable of inducing PLCγ2 phosphorylation (Figure 8A),
suggesting that the mechanism by which TNF-α regulates JNK
and IκBα is PLCγ2 independent. This result prompted us to determine whether TNF-α could rescue the osteoclastogenic defect of
Plcg2–/– cells. Interestingly, while TNF-α augmented RANKL-mediated osteoclastogenesis of WT cells (WT OCs without TNF-α,
19.3 ± 1.5/well; WT OCs with TNF-α, 45.3 ± 1.99/well), the cytokine
did not have any effect on the null cells, which remained blocked
at the early stage of OC development (Plcg2–/– OCs, not detected)
(Figure 8B). Consistent with this finding, TNF-α, compared with
RANKL, was not capable of promoting NFATc1 upregulation in
WT or in PLCγ2-null cells (Figure 8C).
Discussion
The interaction between the immune and skeletal systems is a significant cause of pathological bone loss in rheumatoid arthritis,
periodontal diseases, and tumor-associated bone metastasis (38).
2874
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This exaggerated bone loss is most frequently due to abnormal
activation of the immune system, leading to hyperstimulation
and differentiation of the OCs (2, 39). The identification of signaling pathways or molecules common to the immune and bone
systems could help in designing therapies for the variety of diseases that affect both bone and immunity. Recently, an activating point mutation in the murine PLCγ2 gene has been shown
to lead to severe spontaneous inflammation and autoimmunity,
mediated by B cells and non-B and non-T hematopoietic cells (40).
The chronic inflammation resulted in severe arthritis of the small
joints, leading to phalangeal erosion (40). This observation suggested that the activating mutation in PLCγ2 gene could also be
responsible for the hyperactivation and recruitment of the OCs at
the inflammatory sites.
In this study we have identified what we believe to be a novel role
for the immunomodulatory protein PLCγ2 as a key factor in the
regulation of bone homeostasis. Targeted deletion of Plcg2 led to
increased bone mass due to blockade of OC differentiation in unmanipulated mice, with decreased RANKL-mediated signaling to AP1
and NF-κB and defective upregulation of NFATc1, independent of
PLCγ1. Despite the presence of normal levels of PLCγ1 in the PLCγ2null cells, PLCγ1 could not compensate for the lack of its cognate
isoform. Furthermore, we found that PLCγ2, and not PLCγ1, was
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Figure 7
PLCγ2 forms a complex with GAB2 and modulates its activation. (A) WT preOCs cultured with or without the PLC inhibitor U73122 (5 μM) for
3 days were stimulated with RANKL and subjected to Western blot analysis for phospho-JNK, phospho-IκBα, and NFATc1. β-Actin served as
control. (B) WT and Plcg2–/– BMMs retrovirally transduced with empty vector (pMX), WT PLCγ2, or catalytically inactive PLCγ2 (PLCγ2 H/F) were
cultured with RANKL (100 ng/ml) and M-CSF (10 ng/ml) for 7 days, and multinucleated OCs were detected by TRAP staining. Objective, ×10. (C)
The same cells as shown in B were subjected to RANKL stimulation and Western blot analysis to detect NFATc1 expression. (D) Plcg2–/– BMMs
retrovirally transduced with pMX, WT PLCγ2, or PLCγ2 H/F were treated with RANKL, and phosphorylation of IκBα and JNK was determined by
Western blot analysis. PLCγ2 expression levels are shown. β-Actin served as loading control in C and D. (E) PLCγ2 and GAB2 were reciprocally
immunoprecipitated in WT and Plcg2–/– BMMs treated with RANKL and subjected to Western blot analysis using anti-PLCγ2 and anti-GAB2 Abs,
respectively. TCL, total cell lysate. (F) GAB2 was immunoprecipitated in WT and Plcg2–/– BMMs and subjected to Western blot analysis using
anti-phosphotyrosine Ab (clone 4G10), anti-RANK, and anti-PLCγ2.

phosphorylated by RANKL. This result suggests that the 2 PLCγ
isoforms exert different, nonoverlapping functions in OCs.
Differential regulation of the 2 PLCγ isoforms within the same
cell type has been previously demonstrated in platelets, where
activation of glycoprotein VI by collagen resulted in a substantial
increase in tyrosine phosphorylation of PLCγ2 but not PLCγ1 (41,
42). Since activation of PLCγ isoforms is tightly regulated by the
action of a number of receptor tyrosine kinases (RTKs) (24–26),
we asked whether M-CSF, via its receptor c-Fms, could lead to
phosphorylation of PLCγ1, PLCγ2, or both. We found that PLCγ1,
and to a lesser extent PLCγ2, was phosphorylated by M-CSF. In
support of this finding, analysis of Plcg1–/– ES cells generated few
hematopoietic cells with a reduced level of monocyte/macrophage
differentiation (29). Furthermore, we did not detect an M-CSF–
dependent proliferative defect in BMMs and OCs lacking PLCγ2,
and we observed that M-CSF–mediated activation of ERK and
JNK occurred normally. These results indicate that PLCγ2 is not
The Journal of Clinical Investigation

involved in M-CSF signaling and suggest that PLCγ1 may regulate
this pathway in OC lineage cells.
The phosphorylation of PLCγ2 in response to RANKL was mediated in an SFK-dependent manner. PP2, a well-known Src kinase
inhibitor, completely blocked RANKL-mediated PLCγ2 activation.
Moreover Dap12 was required for phosphorylation of PLCγ2 in
response to RANKL stimulation. It is possible that SFKs phosphorylate PLCγ2 directly. However, it is more likely that SFKs phosphorylate the tyrosine residues in the ITAM motif of Dap12, leading to
recruitment and activation of Syk, which in turn can activate PLCγ,
as occurs in other cell types (B cells and mast cells) (43, 44). We did
not determine which Src family member is involved in PLCγ2 activation, since the inhibitor used blocked various SFKs. These results
indicate that PLCγ isoforms are differentially phosphorylated in
OCs, PLCγ2 primarily by RANKL and PLCγ1 by M-CSF.
AP1, NF-κB, and NFATc1 are members of well-described osteoclastogenic pathways activated by RANKL. We found that PLCγ2
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Figure 8
TNF-α cannot correct the Plcg2–/– OC defect. (A) WT and Plcg2–/–
BMMs were stimulated with TNF-α (10 ng/ml) with time. Phosphorylated
JNK, IκBα, and PLCγ2 were examined. β-Actin served as control. (B)
WT and Plcg2–/– BMMs were cultured for 3 days with RANKL (100
ng/ml) and M-CSF (10 ng/ml). On day 3 TNF-α was also added to the
culture media. Cells were fixed and TRAP stained at day 7. Magnification, ×200. (C) WT and Plcg2–/– preOCs were stimulated with TNF-α
or RANKL for the indicated times, and expression levels of NFATc1,
PLCγ2, and β-actin were determined.

differentially regulates the activation of all them. On one hand,
inhibition of PLCγ2 catalytic activity by U73122 completely abrogated NFATc1 expression in osteoclastic cells but had no effect on
activation of JNK or phosphorylation of IκBα. On the other hand,
we found that p65 translocation into the nucleus and consequent
NF-κB activation determined by EMSA were virtually absent in
PLCγ2-deficient BMMs. Similarly, phospho-JNK levels, nuclear
translocation of phospho–c-Jun, and thus activation of AP1 were
also aberrant in the null cells. Therefore, these data suggest PLCγ2
catalytic activity is required for NFATc1 expression but not for
JNK and IκBα phosphorylation. In agreement with this hypothesis, a catalytically inactive mutant of PLCγ2 could rescue neither
the osteoclastogenic defect of cells lacking PLCγ2 nor NFATc1
upregulation, while being sufficient to promote JNK and IκBα
phosphorylation in response to RANKL. Interestingly, the finding
that PLCγ2 is activated by RANKL downstream of Dap12 and governs all the above-mentioned signaling pathways differs from the
data obtained with cells lacking Dap12 and FcRγ. In fact, Dap12–/–
FcRγ–/– OCs displayed normal RANKL-mediated phosphorylation
of JNK, c-Jun, and IκBα, while NFATc1 upregulation was absent
(20). These results suggest that PLCγ2 may not be uniquely involved
in the signaling cascade downstream of Dap12/FcRγ receptor and
in fact indicate that PLCγ2 regulates JNK and IκBα phosphorylation downstream of RANKL independent of Dap12/FcRγ.
The adapter protein GAB2 has been shown to be a crucial component of RANK signaling and osteoclastogenesis and is required
for activation of NF-κB and JNK, but not NFATc1, pathways (16).
Based on the observation that PLCγ2 forms a complex with GAB2
in OCs and in other cell types (36), we hypothesized that PLCγ2
could regulate some RANKL signaling pathways by acting as an
adapter molecule. One possibility is that PLCγ2 modulates the
GAB2/RANK complex. In support of this hypothesis, we found
that PLCγ2 is required for GAB2 phosphorylation and mediates
2876
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GAB2 recruitment to RANK, suggesting that AP1 and NF-κB
activation might be dependent on the capacity of PLCγ2 to form a
complex with GAB2. In addition, the finding that the PLC inhibitor U73122, which blocks IP3-mediated calcium influx (45), and
a catalytically inactive form of PLCγ2 completely abrogate osteoclastogenesis by affecting NFATc1 upregulation suggest that
both the catalytic activity and the adapter function of PLCγ2
are required for osteoclastogenesis. Thus, overall our data support the model (Figure 9) in which the catalytic activity of PLCγ2
is required for NFATc1 upregulation downstream of the ITAM
motif of Dap12, while PLCγ2, acting as an adapter molecule,
mediates GAB2 phosphorylation and its recruitment to RANK,
leading to AP1 and NF-κB activation.
The specific requirement of PLCγ2 for activation of NF-κB, AP1,
and NFATc1 signaling pathways is manifested in a basal in vivo
osteopetrotic phenotype characterized by defective OC recruitment. Although the number of OCs in vivo was significantly
reduced in Plcg2-null compared with WT animals, the presence of
a few TRAP-positive cells could reflect the presence of a milieu of
cytokines circulating in vivo that partially rescue the differentiation
of PLCγ2-null OCs. TNF-α potently stimulates osteoclastogenesis
by augmenting RANKL-mediated signaling pathways (46). TNF-α
can also induce JNK and IκBα phosphorylation (37). Thus, we
sought to determine whether TNF-α could reverse the ability of the
PLCγ2-null cells to become OCs. Interestingly, while TNF-α could
activate JNK and IκBα in Plcg2–/– BMMs, it could not reverse their
differentiation defect, most likely due to the inability of TNF-α to
induce NFATc1 upregulation. In conclusion, our data indicate that
PLCγ2 is required for the maintenance of bone homeostasis and
RANKL-mediated osteoclastogenesis both in vitro and in vivo.
Previous studies reported that Plcg2–/– mice have defective B
cell maturation and mast cell activation (29). The inability of
Plcg2–/– cells to respond to both basal and inflammation-mediated
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Figure 9
PLCγ2 in RANKL signaling. PLCγ2 is phosphorylated by RANKL in
an SFK-dependent manner downstream of Dap12/FcRγ. Activation of PLCγ2 and PLCγ2 catalytic activity are required for NFATc1
upregulation (right arm). PLCγ2 can also bind GAB2 and modulate its
activation and recruitment to the RANK-signaling complex (left arm).
This interaction might be required for activation of the IκBα/NF-κB and
JNK/AP1 pathways independent of Dap12/FcRγ.

osteoclastogenesis in vitro clearly supports the important role of
PLCγ2 in osteoclast differentiation. Thus, the intrinsic defect of
Plcg2–/– OCs together with the deficient B cell–mediated immune
response suggest that targeting PLCγ2 could be a novel approach
for antiresorptive therapies. Antirheumatic therapies directed to
selectively deplete human CD20-positive B cells (e.g., Rituximab)
or to directly target OC activation and function (RANKL inhibitors and bisphosphonates) have been very useful approaches in
recent clinical trials (47). However, in most cases, only a combination of both treatments will resolve both the inflammatory
and the ongoing osteolytic responses. Thus, PLCγ2 becomes an
interesting target for the cure of rheumatoid diseases due to its
dual role in the activation of a particular subset of immune cells,
B lymphocytes, and for its capacity to control OC development
in vivo. Therefore, a combined therapy affecting both the inflammatory and the osteolytic components of the rheumatoid disease
might increase the hope that disease modification and remission
in rheumatoid arthritis is a realistic goal.
Methods
Mice. Plcg2–/–, Dap12–/–FcRγ–/–, and WT mice were on a C57BL/6 background
and have been previously described (20, 29). All mice used in these experiments were 6−16 weeks old and bred and maintained with sterilized food,
water, and bedding at the Animal Facility of the Washington University
School of Medicine. All experiments were approved by the Animal Studies
Committee of Washington University.
Histology and μCT. Five-micron sections of fixed, decalcified, paraffinembedded long bones were stained with either H&E or histochemically for
TRAP to detect OCs. Calvariae from mice injected with calcein (20 mg/kg
dissolved in 2% NaHCO3; Sigma-Aldrich) were embedded in plastic. For
μCT, 3D images from intact mouse femurs were obtained on a μCT40
scanner (Scanco Medical).
Mouse OCs. BMMs were isolated from long bones of 6- to 8-week-old mice
as described previously (48). We obtained OCs by culturing BMMs with
The Journal of Clinical Investigation

glutathione-S-transferase–RANKL (GST-RANKL) (100 ng/ml) and M-CSF
(10 ng/ml) for 5 days. For coculture experiments, OBs and BMMs were
mixed and cultured for 10–14 days in the presence of 1,25 Vit D3 (10–8 M).
For rescue experiments, macrophages were obtained as described above;
transduced with Flag-Dap12, Flag-PLCγ2, or Flag-PLCγ2 H/F; selected in
puromycin- (for Dap12 constructs) or blastocydin-containing media (for
PLCγ2 constructs) for 3 days; and cultured with M-CSF and RANKL to
obtain OCs, as previously described (49). The PLCγ2 H/F mutation was
made using a QuikChange XL Site-Directed Mutagenesis Kit (catalog
200517; Stratagene) following the manufacturer’s instructions.
Mouse OBs. We isolated OB precursors from calvariae of mice that were 4
days old, expanded them in media alone until confluent, and then cultured
them with β-glycerolphosphate and ascorbic acid to induce OB differentiation until bone nodules formed.
Western blot analysis and antibodies. BMMs or OCs starved for 6 hours
in serum-free medium were stimulated with RANKL (100 ng/ml) or
M-CSF (100 ng/ml) and lysed at the times indicated in the Results and
Figures 4–8 in RIPA lysis buffer supplemented with protease inhibitors
and sodium orthovanadate. In some experiments, OCs were cultured in
the presence of the Src inhibitor PP2 (5 μM; Calbiochem) or PLC inhibitor U73122 (5 μM; Biomol), starved, and then stimulated with RANKL.
For Western blot analysis of phospho-PLCγ1 and -PLCγ2, phospho-ERK,
phospho-JNK, phospho–c-Jun, phospho-IκBα, and phospho-Src (Y416),
we used polyclonal antibodies from Cell Signaling Technology. Polyclonal
antiserum against p65, NFATc1, and PLCγ2 were purchased from Santa
Cruz Biotechnology Inc. The monoclonal antibody against β-actin was
obtained from Sigma-Aldrich. Polyclonal GAB2 Ab was purchased from
Upstate USA Inc. To obtain nuclear extract from RANKL-treated cells,
plates were washed with H2O and cells lysed with hypotonic buffer
(10 mM HEPES, 1.5 mM MgCl2, 1 mM KCl, 1 mM DTT, and protease and
phosphatase inhibitors), followed by addition of 0.1% NP40. After centrifugation, the supernatants were collected (cytosolic fraction), while the
pellets (nuclear fraction) were suspended in high-salt buffer (hypotonic
buffer plus 400 mM NaCl). Extracts were quantified by a modified Coomassie method (Pierce). Nonradioactive EMSA was performed following
the manufacturer’s instructions (Pierce) using AP1 and NF-κB biotinylated oligonucleotides (for AP1: 5′ Biotin-ACGCTTGATGACTCAGCCGGAAT-3′ and 5′ Biotin-ATTCCGGCTGAGTCATCAAGC-3′; for NF-κB: 5′
Biotin-AAGTTGAGGGGACTTTCCCAGGCT-3′ and 5′ Biotin-AGCCTGGGAAAGTCCCCTCAACTT-3′). An excess (200×) of nonbiotinylated
oligonucleotides was used for competition control.
Immunofluorescence. WT or Dap12–/–FcRγ–/– OCs retrovirally transduced
with either the empty vector or full-length Dap12 were cultured on glass,
fixed, and stained with anti-NFATc1 Ab (Santa Cruz Biotechnology Inc.),
DAPI to detect the nuclei, and FITC-phalloidin to detect actin (48).
Real-time PCR. Total RNA was isolated from cell cultures at various
times using the RNeasy Mini Kit (Qiagen) and was reverse transcribed
to cDNAs using SuperScript II according to the manufacturer’s instructions (Invitrogen). Primers specific for murine NFATc1, TRAP, GAPDH,
cathepsin K, and calcitonin receptor were used. For quantitative real-time
PCR, NFATc1 was amplified using 5′-CCCGTCACATTCTGGTCCAT-3′
and 5′-CAAGTAACCGTGTAGCTGCACAA-3′.
TRAP was amplified using 5′-CAGCTCCCTAGAAGATGGATTCAT3′ and 5′-GTCAGGAGTGGGAGCCATATG-3′; β-actin using 5′-CTTCTACAATGAGCTGCGTG-3′ and 5′-TCATGAGGTAGTCTGTCAGG3′; cathepsin K using 5′-ATGTGGGTGTTCAAGTTTCTGC-3′ and
5′-CCACAAGATTCTGGGGACTC-3′; and calcitonin receptor using
5′-CAAGAACCTTAGCTGCCAGAG-3′ and 5′-CAAGCACGCGGACAATGTTG-3′. SYBR green dye was used for detection of the product using the
SYBR Green PCR Master Mix assay (Applied Biosystems). The standard
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curve used a series of duplicate dilutions of plasmid for each gene and
β-actin cDNA. The amplification reaction was performed for 40 cycles with
denaturation at 95°C for 10 minutes, followed by annealing at 95°C for
15 seconds and extension and detection at 60°C for 1 minute. The relative RNA abundance of each target gene transcript was normalized against
endogenous gene control and calculated as 2–Δct(target gene – endogenous control gene),
where ct represents the threshold cycle for each transcript.
Statistics. All data are presented as mean ± SEM. Values with P < 0.05 were
considered significant as determined by 2-tailed Student’s t test (SigmaPlot
version 8; Systat).
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